---
document_datetime: 2025-12-02 05:01:14
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/atazanavir-krka.html
document_name: atazanavir-krka.html
version: success
processing_time: 0.1239059
conversion_datetime: 2025-12-28 03:50:33.207203
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Atazanavir Krka

[RSS](/en/individual-human-medicine.xml/67185)

##### Authorised

This medicine is authorised for use in the European Union

atazanavir Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Atazanavir Krka](#news-on)
- [Related content](#related-content-1554)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Atazanavir Krka is an HIV medicine used to treat patients infected with human immunodeficiency virus type 1 (HIV-1), a virus that causes acquired immunodeficiency syndrome (AIDS). It is used together with low-dose ritonavir and other antiviral medicines to treat patients aged 6 years and over.

Doctors should prescribe Atazanavir Krka only after they have looked at which medicines the patient has taken and carried out tests to establish that the virus is likely to respond to Atazanavir Krka. The medicine is not expected to work in patients in whom many medicines in the same class as Atazanavir Krka (protease inhibitors) do not work.

Atazanavir Krka contains the active substance atazanavir and is a 'generic medicine'. This means that Atazanavir Krka contains the same active substance and works in the same way as a 'reference medicine' already authorised in the EU called Reyataz.

Expand section

Collapse section

## How is Atazanavir Krka used?

Atazanavir Krka is available as capsules (150 mg, 200 mg and 300 mg). It can only be obtained with a prescription and treatment should be started by a doctor who has experience in the treatment of HIV infection.

For adults, the recommended dose is 300 mg once a day. In younger patients, the dose of Atazanavir Krka depends on body weight. Each dose must be taken with food.

Atazanavir Krka is normally given with ritonavir to boost its action but doctors can consider stopping ritonavir in adults in some specific situations.

For more information about using Atazanavir Krka, see the package leaflet or contact your doctor or pharmacist.

## How does Atazanavir Krka work?

The active substance in Atazanavir Krka, atazanavir, is a protease inhibitor. It blocks an enzyme called protease, which is needed for the HIV virus to multiply. Blocking the enzyme prevents the virus from multiplying, slowing down the spread of infection. A small dose of another medicine, ritonavir, is normally given at the same time as a 'booster'. Ritonavir slows down the break-down of atazanavir, increasing the levels of atazanavir in the blood. This allows a lower dose of atazanavir to be used for the same antiviral effect. Atazanavir Krka, taken in combination with other antiviral medicines, reduces the amount of HIV in the blood and keeps it at a low level. Atazanavir Krka does not cure HIV infection or AIDS but, when used in combination with other antivirals, it holds off the damage to the immune system and the development of infections and diseases associated with AIDS.

## How has Atazanavir Krka been studied?

Studies on the benefits and risks of the active substance in the authorised use have already been carried out with the reference medicine, Reyataz, and do not need to be repeated for Atazanavir Krka.

As for every medicine, the company provided studies on the quality of Atazanavir Krka. The company also carried out a study that showed that it is 'bioequivalent' to the reference medicine. Two medicines are bioequivalent when they produce the same levels of the active substance in the body and are therefore expected to have the same effect.

## What are the benefits and risks of Atazanavir Krka?

Because Atazanavir Krka is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.

## Why is Atazanavir Krka authorised in the EU?

The European Medicines Agency concluded that, in accordance with EU requirements, Atazanavir Krka has been shown to have comparable quality and to be bioequivalent to Reyataz. Therefore, the Agency's view was that, as for Reyataz, the benefit of Atazanavir Krka outweighs the identified risk and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Atazanavir Krka?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Atazanavir Krka have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Atazanavir Krka are continuously monitored. Side effects reported with Atazanavir Krka are carefully evaluated and any necessary action taken to protect patients.

## Other information about Atazanavir Krka

Atazanavir Krka received a marketing authorisation valid throughout the EU on 25 March 2019.

Atazanavir Krka : EPAR - Medicine overview

Reference Number: EMA/107659/2019

English (EN) (96.72 KB - PDF)

**First published:** 15/05/2019

[View](/en/documents/overview/atazanavir-krka-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-940)

български (BG) (119.37 KB - PDF)

**First published:**

15/05/2019

[View](/bg/documents/overview/atazanavir-krka-epar-medicine-overview_bg.pdf)

español (ES) (93.42 KB - PDF)

**First published:**

15/05/2019

[View](/es/documents/overview/atazanavir-krka-epar-medicine-overview_es.pdf)

čeština (CS) (115.36 KB - PDF)

**First published:**

15/05/2019

[View](/cs/documents/overview/atazanavir-krka-epar-medicine-overview_cs.pdf)

dansk (DA) (91.56 KB - PDF)

**First published:**

15/05/2019

[View](/da/documents/overview/atazanavir-krka-epar-medicine-overview_da.pdf)

Deutsch (DE) (94.26 KB - PDF)

**First published:**

15/05/2019

[View](/de/documents/overview/atazanavir-krka-epar-medicine-overview_de.pdf)

eesti keel (ET) (90.97 KB - PDF)

**First published:**

15/05/2019

[View](/et/documents/overview/atazanavir-krka-epar-medicine-overview_et.pdf)

ελληνικά (EL) (127.17 KB - PDF)

**First published:**

15/05/2019

[View](/el/documents/overview/atazanavir-krka-epar-medicine-overview_el.pdf)

français (FR) (93.74 KB - PDF)

**First published:**

15/05/2019

[View](/fr/documents/overview/atazanavir-krka-epar-medicine-overview_fr.pdf)

hrvatski (HR) (110.86 KB - PDF)

**First published:**

15/05/2019

[View](/hr/documents/overview/atazanavir-krka-epar-medicine-overview_hr.pdf)

italiano (IT) (91.58 KB - PDF)

**First published:**

15/05/2019

[View](/it/documents/overview/atazanavir-krka-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (113.76 KB - PDF)

**First published:**

15/05/2019

[View](/lv/documents/overview/atazanavir-krka-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (112.98 KB - PDF)

**First published:**

15/05/2019

[View](/lt/documents/overview/atazanavir-krka-epar-medicine-overview_lt.pdf)

magyar (HU) (113.34 KB - PDF)

**First published:**

15/05/2019

[View](/hu/documents/overview/atazanavir-krka-epar-medicine-overview_hu.pdf)

Malti (MT) (123.09 KB - PDF)

**First published:**

15/05/2019

[View](/mt/documents/overview/atazanavir-krka-epar-medicine-overview_mt.pdf)

Nederlands (NL) (93.28 KB - PDF)

**First published:**

15/05/2019

[View](/nl/documents/overview/atazanavir-krka-epar-medicine-overview_nl.pdf)

polski (PL) (116.85 KB - PDF)

**First published:**

15/05/2019

[View](/pl/documents/overview/atazanavir-krka-epar-medicine-overview_pl.pdf)

português (PT) (92.09 KB - PDF)

**First published:**

15/05/2019

[View](/pt/documents/overview/atazanavir-krka-epar-medicine-overview_pt.pdf)

română (RO) (114.44 KB - PDF)

**First published:**

15/05/2019

[View](/ro/documents/overview/atazanavir-krka-epar-medicine-overview_ro.pdf)

slovenčina (SK) (115.12 KB - PDF)

**First published:**

15/05/2019

[View](/sk/documents/overview/atazanavir-krka-epar-medicine-overview_sk.pdf)

slovenščina (SL) (109.82 KB - PDF)

**First published:**

15/05/2019

[View](/sl/documents/overview/atazanavir-krka-epar-medicine-overview_sl.pdf)

Suomi (FI) (91.29 KB - PDF)

**First published:**

15/05/2019

[View](/fi/documents/overview/atazanavir-krka-epar-medicine-overview_fi.pdf)

svenska (SV) (91.62 KB - PDF)

**First published:**

15/05/2019

[View](/sv/documents/overview/atazanavir-krka-epar-medicine-overview_sv.pdf)

Atazanavir Krka : EPAR - Risk-management-plan summary

English (EN) (112.3 KB - PDF)

**First published:** 15/05/2019

[View](/en/documents/rmp-summary/atazanavir-krka-epar-risk-management-plan-summary_en.pdf)

## Product information

Atazanavir Krka : EPAR - Product information

English (EN) (486.23 KB - PDF)

**First published:** 15/05/2019

**Last updated:** 03/06/2025

[View](/en/documents/product-information/atazanavir-krka-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-951)

български (BG) (407.76 KB - PDF)

**First published:**

15/05/2019

**Last updated:**

03/06/2025

[View](/bg/documents/product-information/atazanavir-krka-epar-product-information_bg.pdf)

español (ES) (374.76 KB - PDF)

**First published:**

15/05/2019

**Last updated:**

03/06/2025

[View](/es/documents/product-information/atazanavir-krka-epar-product-information_es.pdf)

čeština (CS) (365.38 KB - PDF)

**First published:**

15/05/2019

**Last updated:**

03/06/2025

[View](/cs/documents/product-information/atazanavir-krka-epar-product-information_cs.pdf)

dansk (DA) (383.61 KB - PDF)

**First published:**

15/05/2019

**Last updated:**

03/06/2025

[View](/da/documents/product-information/atazanavir-krka-epar-product-information_da.pdf)

Deutsch (DE) (414.26 KB - PDF)

**First published:**

15/05/2019

**Last updated:**

03/06/2025

[View](/de/documents/product-information/atazanavir-krka-epar-product-information_de.pdf)

eesti keel (ET) (355.84 KB - PDF)

**First published:**

15/05/2019

**Last updated:**

03/06/2025

[View](/et/documents/product-information/atazanavir-krka-epar-product-information_et.pdf)

ελληνικά (EL) (404.42 KB - PDF)

**First published:**

15/05/2019

**Last updated:**

03/06/2025

[View](/el/documents/product-information/atazanavir-krka-epar-product-information_el.pdf)

français (FR) (385.57 KB - PDF)

**First published:**

15/05/2019

**Last updated:**

03/06/2025

[View](/fr/documents/product-information/atazanavir-krka-epar-product-information_fr.pdf)

hrvatski (HR) (376.52 KB - PDF)

**First published:**

15/05/2019

**Last updated:**

03/06/2025

[View](/hr/documents/product-information/atazanavir-krka-epar-product-information_hr.pdf)

íslenska (IS) (362.97 KB - PDF)

**First published:**

15/05/2019

**Last updated:**

03/06/2025

[View](/is/documents/product-information/atazanavir-krka-epar-product-information_is.pdf)

italiano (IT) (369.5 KB - PDF)

**First published:**

15/05/2019

**Last updated:**

03/06/2025

[View](/it/documents/product-information/atazanavir-krka-epar-product-information_it.pdf)

latviešu valoda (LV) (373.51 KB - PDF)

**First published:**

15/05/2019

**Last updated:**

03/06/2025

[View](/lv/documents/product-information/atazanavir-krka-epar-product-information_lv.pdf)

lietuvių kalba (LT) (368.27 KB - PDF)

**First published:**

15/05/2019

**Last updated:**

03/06/2025

[View](/lt/documents/product-information/atazanavir-krka-epar-product-information_lt.pdf)

magyar (HU) (406.79 KB - PDF)

**First published:**

15/05/2019

**Last updated:**

03/06/2025

[View](/hu/documents/product-information/atazanavir-krka-epar-product-information_hu.pdf)

Malti (MT) (458.6 KB - PDF)

**First published:**

15/05/2019

**Last updated:**

03/06/2025

[View](/mt/documents/product-information/atazanavir-krka-epar-product-information_mt.pdf)

Nederlands (NL) (384.96 KB - PDF)

**First published:**

15/05/2019

**Last updated:**

03/06/2025

[View](/nl/documents/product-information/atazanavir-krka-epar-product-information_nl.pdf)

norsk (NO) (372.24 KB - PDF)

**First published:**

15/05/2019

**Last updated:**

03/06/2025

[View](/no/documents/product-information/atazanavir-krka-epar-product-information_no.pdf)

polski (PL) (388.56 KB - PDF)

**First published:**

15/05/2019

**Last updated:**

03/06/2025

[View](/pl/documents/product-information/atazanavir-krka-epar-product-information_pl.pdf)

português (PT) (374.95 KB - PDF)

**First published:**

15/05/2019

**Last updated:**

03/06/2025

[View](/pt/documents/product-information/atazanavir-krka-epar-product-information_pt.pdf)

română (RO) (388.07 KB - PDF)

**First published:**

15/05/2019

**Last updated:**

03/06/2025

[View](/ro/documents/product-information/atazanavir-krka-epar-product-information_ro.pdf)

slovenčina (SK) (378.05 KB - PDF)

**First published:**

15/05/2019

**Last updated:**

03/06/2025

[View](/sk/documents/product-information/atazanavir-krka-epar-product-information_sk.pdf)

slovenščina (SL) (381.11 KB - PDF)

**First published:**

15/05/2019

**Last updated:**

03/06/2025

[View](/sl/documents/product-information/atazanavir-krka-epar-product-information_sl.pdf)

Suomi (FI) (391.97 KB - PDF)

**First published:**

15/05/2019

**Last updated:**

03/06/2025

[View](/fi/documents/product-information/atazanavir-krka-epar-product-information_fi.pdf)

svenska (SV) (363.21 KB - PDF)

**First published:**

15/05/2019

**Last updated:**

03/06/2025

[View](/sv/documents/product-information/atazanavir-krka-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000273939 03/06/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Atazanavir Krka : EPAR - All authorised presentations

English (EN) (14.92 KB - PDF)

**First published:** 15/05/2019

[View](/en/documents/all-authorised-presentations/atazanavir-krka-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-228)

български (BG) (34.24 KB - PDF)

**First published:**

15/05/2019

[View](/bg/documents/all-authorised-presentations/atazanavir-krka-epar-all-authorised-presentations_bg.pdf)

español (ES) (14.17 KB - PDF)

**First published:**

15/05/2019

[View](/es/documents/all-authorised-presentations/atazanavir-krka-epar-all-authorised-presentations_es.pdf)

čeština (CS) (28.3 KB - PDF)

**First published:**

15/05/2019

[View](/cs/documents/all-authorised-presentations/atazanavir-krka-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (14.95 KB - PDF)

**First published:**

15/05/2019

[View](/da/documents/all-authorised-presentations/atazanavir-krka-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (15.15 KB - PDF)

**First published:**

15/05/2019

[View](/de/documents/all-authorised-presentations/atazanavir-krka-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (14.93 KB - PDF)

**First published:**

15/05/2019

[View](/et/documents/all-authorised-presentations/atazanavir-krka-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (32.19 KB - PDF)

**First published:**

15/05/2019

[View](/el/documents/all-authorised-presentations/atazanavir-krka-epar-all-authorised-presentations_el.pdf)

français (FR) (14.27 KB - PDF)

**First published:**

15/05/2019

[View](/fr/documents/all-authorised-presentations/atazanavir-krka-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (27.93 KB - PDF)

**First published:**

15/05/2019

[View](/hr/documents/all-authorised-presentations/atazanavir-krka-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (13.58 KB - PDF)

**First published:**

15/05/2019

[View](/is/documents/all-authorised-presentations/atazanavir-krka-epar-all-authorised-presentations_is.pdf)

italiano (IT) (14.77 KB - PDF)

**First published:**

15/05/2019

[View](/it/documents/all-authorised-presentations/atazanavir-krka-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (32.92 KB - PDF)

**First published:**

15/05/2019

[View](/lv/documents/all-authorised-presentations/atazanavir-krka-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (33.31 KB - PDF)

**First published:**

15/05/2019

[View](/lt/documents/all-authorised-presentations/atazanavir-krka-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (27.93 KB - PDF)

**First published:**

15/05/2019

[View](/hu/documents/all-authorised-presentations/atazanavir-krka-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (28.72 KB - PDF)

**First published:**

15/05/2019

[View](/mt/documents/all-authorised-presentations/atazanavir-krka-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (14.18 KB - PDF)

**First published:**

15/05/2019

[View](/nl/documents/all-authorised-presentations/atazanavir-krka-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (15.29 KB - PDF)

**First published:**

15/05/2019

[View](/no/documents/all-authorised-presentations/atazanavir-krka-epar-all-authorised-presentations_no.pdf)

polski (PL) (30.35 KB - PDF)

**First published:**

15/05/2019

[View](/pl/documents/all-authorised-presentations/atazanavir-krka-epar-all-authorised-presentations_pl.pdf)

português (PT) (13.39 KB - PDF)

**First published:**

15/05/2019

[View](/pt/documents/all-authorised-presentations/atazanavir-krka-epar-all-authorised-presentations_pt.pdf)

română (RO) (22.83 KB - PDF)

**First published:**

15/05/2019

[View](/ro/documents/all-authorised-presentations/atazanavir-krka-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (28.5 KB - PDF)

**First published:**

15/05/2019

[View](/sk/documents/all-authorised-presentations/atazanavir-krka-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (20.01 KB - PDF)

**First published:**

15/05/2019

[View](/sl/documents/all-authorised-presentations/atazanavir-krka-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (14.51 KB - PDF)

**First published:**

15/05/2019

[View](/fi/documents/all-authorised-presentations/atazanavir-krka-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (14.93 KB - PDF)

**First published:**

15/05/2019

[View](/sv/documents/all-authorised-presentations/atazanavir-krka-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Atazanavir Krka Active substance atazanavir (as sulfate) International non-proprietary name (INN) or common name atazanavir Therapeutic area (MeSH) HIV Infections Anatomical therapeutic chemical (ATC) code J05AE08

### Pharmacotherapeutic group

Antivirals for systemic use

### Therapeutic indication

Atazanavir Krka capsules, co-administered with low dose ritonavir, are indicated for the treatment of HIV-1 infected adults and paediatric patients 6 years of age and older in combination with other antiretroviral medicinal products.

Based on available virological and clinical data from adult patients, no benefit is expected in patients with strains resistant to multiple protease inhibitors (? 4 PI mutations).

The choice of Atazanavir Krka in treatment experienced adult and paediatric patients should be based on individual viral resistance testing and the patient's treatment history.

## Authorisation details

EMA product number EMEA/H/C/004859

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

Krka, d.d., Novo mesto

KRKA d.d., Novo mesto

Opinion adopted 31/01/2019 Marketing authorisation issued 25/03/2019 Revision 3

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Atazanavir Krka : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (147.7 KB - PDF)

**First published:** 03/06/2025

[View](/en/documents/procedural-steps-after/atazanavir-krka-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Atazanavir Krka : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (87.87 KB - PDF)

**First published:** 09/12/2021

**Last updated:** 03/06/2025

[View](/en/documents/procedural-steps-after/atazanavir-krka-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

## Initial marketing authorisation documents

Atazanavir Krka : EPAR - Public assessment report

Adopted

Reference Number: EMA/119506/2019

English (EN) (300.38 KB - PDF)

**First published:** 15/05/2019

[View](/en/documents/assessment-report/atazanavir-krka-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Atazanavir Krka

Adopted

Reference Number: EMA/CHMP/17181/2019

English (EN) (79.77 KB - PDF)

**First published:** 01/02/2019

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-atazanavir-krka_en.pdf)

#### News on Atazanavir Krka

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 28-31 January 2019](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-28-31-january-2019) 01/02/2019

#### Related content

Questions and answers on generic medicines

Reference Number: EMA/393905/2006 Rev. 2

English (EN) (66.45 KB - PDF)

**First published:** 09/07/2007

**Last updated:** 07/12/2012

[View](/en/documents/other/questions-and-answers-generic-medicines_en.pdf)

[Other languages (22)](#file-language-dropdown-211)

български (BG) (93.16 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/bg/documents/other/questions-and-answers-generic-medicines_bg.pdf)

español (ES) (68.3 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/es/documents/other/questions-and-answers-generic-medicines_es.pdf)

čeština (CS) (87.71 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/cs/documents/other/questions-and-answers-generic-medicines_cs.pdf)

dansk (DA) (66.79 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/da/documents/other/questions-and-answers-generic-medicines_da.pdf)

Deutsch (DE) (67.55 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/de/documents/other/questions-and-answers-generic-medicines_de.pdf)

eesti keel (ET) (65.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/et/documents/other/questions-and-answers-generic-medicines_et.pdf)

ελληνικά (EL) (91.29 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/el/documents/other/questions-and-answers-generic-medicines_el.pdf)

français (FR) (68.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fr/documents/other/questions-and-answers-generic-medicines_fr.pdf)

hrvatski (HR) (87.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hr/documents/other/questions-and-answers-generic-medicines_hr.pdf)

italiano (IT) (67.62 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/it/documents/other/questions-and-answers-generic-medicines_it.pdf)

latviešu valoda (LV) (111.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lv/documents/other/questions-and-answers-generic-medicines_lv.pdf)

lietuvių kalba (LT) (86.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lt/documents/other/questions-and-answers-generic-medicines_lt.pdf)

magyar (HU) (85.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hu/documents/other/questions-and-answers-generic-medicines_hu.pdf)

Malti (MT) (89.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/mt/documents/other/questions-and-answers-generic-medicines_mt.pdf)

Nederlands (NL) (66.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/nl/documents/other/questions-and-answers-generic-medicines_nl.pdf)

polski (PL) (88.51 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pl/documents/other/questions-and-answers-generic-medicines_pl.pdf)

português (PT) (68.32 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pt/documents/other/questions-and-answers-generic-medicines_pt.pdf)

română (RO) (86.9 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/ro/documents/other/questions-and-answers-generic-medicines_ro.pdf)

slovenčina (SK) (87.73 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sk/documents/other/questions-and-answers-generic-medicines_sk.pdf)

slovenščina (SL) (84.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sl/documents/other/questions-and-answers-generic-medicines_sl.pdf)

Suomi (FI) (66.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fi/documents/other/questions-and-answers-generic-medicines_fi.pdf)

svenska (SV) (67.11 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sv/documents/other/questions-and-answers-generic-medicines_sv.pdf)

#### Topics

- [Generic and hybrid medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A54)
- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 03/06/2025

## Share this page

[Back to top](#main-content)